Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.

medRxiv : the preprint server for health sciences·2026
Same author

Preoperative Orbital Compliance as a Predictor for Outcomes of Fat Decompression in Thyroid Eye Disease.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Transorbital Approach to Surgical Resection of a Far-Lateral Frontal Sinus Osteoma.

Journal of neurological surgery reports·2026
Same author

Relapse Versus Rebound in Thyroid Eye Disease After Teprotumumab Treatment: A Retrospective Case Series.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Outcomes of Hyperbaric Oxygen Therapy at 2.0 Versus 2.5 ATA for Hemorrhagic Radiation Cystitis.

Neurourology and urodynamics·2026
Same author

Systematic Review of Otologic Adverse Events in Hyperbaric Oxygen Therapy.

Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc·2025

Related Experiment Video

Updated: Jul 16, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.1K

Complete Vision Recovery After Filler-Induced Blindness Using Hyperbaric Oxygen Therapy: Case Report and Literature

Rebecca Friedman, Allison V Coombs, Shanlee Stevens

    Aesthetic Surgery Journal. Open Forum
    |June 12, 2024
    PubMed
    Summary

    Facial fillers can cause blindness, but prompt hyperbaric oxygen therapy (HBOT) shows promise for vision recovery. This case highlights HBOT as a potential treatment for filler-induced blindness, advocating for further research.

    More Related Videos

    Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
    09:28

    Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

    Published on: September 16, 2020

    8.4K
    Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
    10:10

    Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

    Published on: February 15, 2022

    1.4K

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
    10:24

    Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

    Published on: February 12, 2018

    10.1K
    Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
    09:28

    Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

    Published on: September 16, 2020

    8.4K
    Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
    10:10

    Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

    Published on: February 15, 2022

    1.4K

    Area of Science:

    • Ophthalmology
    • Dermatology
    • Emergency Medicine

    Background:

    • Soft-tissue fillers, like hyaluronic acid, are popular for facial augmentation.
    • Adverse effects, though rare, can range from cosmetic issues to severe complications like blindness.
    • Filler-induced blindness, a critical adverse event, necessitates established treatment protocols.

    Observation:

    • A 38-year-old female experienced immediate vision loss after injecting mail-order filler into her glabella and eyebrow.
    • Standard treatments including hyaluronidase and ocular massage failed to restore vision.
    • Hyperbaric oxygen therapy (HBOT) was administered within 10 hours of the injury.

    Findings:

    • Prompt HBOT administration led to significant vision improvement.
    • Following two additional HBOT sessions, the patient achieved complete vision recovery.
    • This case demonstrates successful vision restoration using HBOT for filler-induced blindness.

    Implications:

    • HBOT may be a valuable therapeutic option for filler-induced blindness.
    • Further research is warranted to incorporate HBOT into standard treatment algorithms.
    • Increased medical community awareness of HBOT benefits is crucial for patient outcomes.